US 12,280,229 B2
Cerebrospinal fluid purification system
Shivanand Lad, Durham, NC (US); William C. Mobley, La Jolla, CA (US); Karoly Nikolich, Emerald Hill, CA (US); and Thomas Saul, El Granada, CA (US)
Assigned to NEUROFLUIDICS, INC., St. Paul, MN (US)
Filed by NEUROFLUIDICS, INC., St. Paul, MN (US)
Filed on Jun. 22, 2021, as Appl. No. 17/354,388.
Application 17/354,388 is a continuation of application No. 16/548,554, filed on Aug. 22, 2019, granted, now 11,065,425.
Application 16/548,554 is a continuation of application No. 15/410,219, filed on Jan. 19, 2017, granted, now 10,398,884, issued on Sep. 3, 2019.
Application 15/410,219 is a continuation of application No. 13/801,215, filed on Mar. 13, 2013, granted, now 9,895,518, issued on Feb. 20, 2018.
Application 13/801,215 is a continuation of application No. 12/444,581, granted, now 8,435,204, issued on May 7, 2013, previously published as PCT/US2007/080834, filed on Oct. 9, 2007.
Claims priority of provisional application 60/828,745, filed on Oct. 9, 2006.
Prior Publication US 2021/0386981 A1, Dec. 16, 2021
Int. Cl. A61M 27/00 (2006.01); A61M 25/00 (2006.01); A61M 1/36 (2006.01)
CPC A61M 27/006 (2013.01) [A61M 25/0026 (2013.01); A61M 1/3679 (2013.01); A61M 2025/0007 (2013.01); A61M 2027/004 (2013.01); A61M 2202/0021 (2013.01); A61M 2202/0464 (2013.01); A61M 2202/203 (2013.01); A61M 2202/206 (2013.01); A61M 2206/16 (2013.01); A61M 2210/0693 (2013.01); A61M 2210/1003 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A method for ameliorating a symptom of one or more of Amyotrophic Lateral Sclerosis and Huntington's Disease in a patient, said method comprising:
selecting a patient having a symptom of one of Amyotrophic Lateral Sclerosis or Huntington's Disease;
removing cerebrospinal fluid from a first location in a cerebrospinal fluid space of the patient;
removing a causative agent from the removed cerebrospinal fluid, thereby conditioning the cerebrospinal fluid; and
returning the conditioned cerebrospinal fluid to the patient at a second location in the cerebrospinal fluid space of the patient, wherein the cerebrospinal fluid is returned to the patient at substantially the same flow rate at which it is removed;
wherein the conditioned cerebrospinal fluid is free of artificial cerebrospinal fluid; wherein the removing and returning steps are performed concurrently using a single catheter, the single catheter comprising a first lumen with a first proximal port at the first location and a second lumen having a second distal port at the second location during at least a portion of a conditioning treatment;
wherein the first proximal port and the second distal port are axially spaced apart along the single catheter.